Cybin Inc. presented two posters at the American College of Neuropsychopharmacology (ACNP) Annual Meeting, highlighting significant clinical data. The presentations included 12-month efficacy results from the company’s Phase 2 study of CYB003 in Major Depressive Disorder (MDD).
The CYB003 data showed durable response and remission rates at 12 months, with 100% response and 71% remission among participants who received two 16 mg doses. These results reinforce the potential of CYB003 as a transformative treatment for depression.
Additionally, results from a completed Phase 1b study exploring drug-drug interactions between N,N-dimethyltryptamine (DMT) and selective serotonin reuptake inhibitors (SSRIs) were presented. The findings imply that patients may not need to discontinue their antidepressant treatment to undergo psychedelic treatment, and suggest a potentially enhanced efficacy effect when SPL026 (DMT fumarate) was administered with SSRIs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.